ArticleEuropean journal of pediatrics2012
Hereditary angioedema (HAE) in children and adolescents--a consensus on therapeutic strategies.
Article in European journal of pediatrics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- A consensus parameter for the evaluation and management of angioedema in the emergency department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2014Guideline
- The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities.The World Allergy Organization journal · 2026Article
- Delphi Consensus on Attenuated Androgen Use for Long-Term Prophylaxis in Hereditary Angioedema: AURA Project.Clinical and translational allergy · 2025Article
- Etiology, Recent Advances, and Clinical Trials Data for the Treatment of Angioedema: A Review.Reviews on recent clinical trials · 2025Review
- Consensus on diagnosis and management of Hereditary Angioedema in the Middle East: A Delphi initiative.The World Allergy Organization journal · 2023Article
- The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.The World Allergy Organization journal · 2022Article
- Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Article
- Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema.Clinical and translational allergy · 2022Review
- Significant predictive factors of the severity and outcomes of the first attack of acute angioedema in children.BMC pediatrics · 2019Article
- Evaluation and Management of Angioedema in the Emergency Department.The western journal of emergency medicine · 2019Review
- Pediatric Angioedema.Current allergy and asthma reports · 2017Review
- Article
- Review of Select Practice Parameters, Evidence-Based Treatment Algorithms, and International Guidelines for Hereditary Angioedema.Clinical reviews in allergy & immunology · 2016Review
- The Story of Angioedema: from Quincke to Bradykinin.Clinical reviews in allergy & immunology · 2016Review
- Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance.Patient preference and adherence · 2016Review
- Diagnosis and screening of patients with hereditary angioedema in primary care.Therapeutics and clinical risk management · 2016Review
- Upper Airway Obstruction in Children.Indian journal of pediatrics · 2015Review
- The care pathway for children with urticaria, angioedema, mastocytosis.The World Allergy Organization journal · 2015Article
- Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema.Transfusion · 2014Article
- Pediatric hereditary angioedema.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary angioedema due to C1 inhibitor (C1 esterase inhibitor) deficiency (types I and II HAE-C1-INH) is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life-threatening angioedema. Diagnosis as early as possible is important to avoid ineffective therapies and to properly treat swelling attacks. At a consensus meeting in June 2011, pediatricians and dermatologists from Germany, Austria, and Switzerland reviewed the currently available literature, including published international consensus recommendations for HAE therapy across all age groups. Published recommendations cannot be unconditionally adopted for pediatric patients in German-speaking countries given the current approval status of HAE drugs. This article provides an overview and discusses drugs available for HAE therapy, their approval status, and study results obtained in adult and pediatric patients. Recommendations for developing appropriate treatment strategies in the management of HAE in pediatric patients in German-speaking countries are provided.Conclusion Currently, plasma-derived C1 inhibitor concentrate is considered the best available option for the treatment of acute HAE-C1-INH attacks in pediatric patients in German-speaking countries, as well as for short-term and long-term prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.